Market Cap 45.85M
Revenue (ttm) 0.00
Net Income (ttm) -41.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 26,700
Avg Vol 56,168
Day's Range N/A - N/A
Shares Out 4.44M
Stochastic %K 28%
Beta -2.08
Analysts Sell
Price Target $9.00

Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The comp...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 798 8589
Address:
2000 Sierra Point Parkway, Suite 400, Brisbane, United States
HoodyHaz
HoodyHaz Oct. 25 at 4:17 AM
$TPST $TPST Is First out of the gate then to $SLS $ALT 3 best buyout candidates!!
1 · Reply
HoodyHaz
HoodyHaz Oct. 25 at 4:05 AM
$SLS 3 most exciting buyout candidates… $SLS $ALT $TPST TPST 10x ALT 30x SLS 30x Great assets… Best Speculation Plays !! ALL VERY VERY SOON…One goes into the other 2…. Then your liftoff…
0 · Reply
Letsinvest2024
Letsinvest2024 Oct. 24 at 11:42 PM
$TPST can’t wait for my 50k reward here🥳
1 · Reply
lousjamsession
lousjamsession Oct. 24 at 9:08 PM
1 · Reply
Dannyb313
Dannyb313 Oct. 24 at 8:32 PM
$TPST The track record of the companies Stephen Brady was instrumental in selling is indeed exceptional: • Proteolix's drug, Kyprolis (carfilzomib), became a game-changing, standard-of-care drug for Multiple Myeloma and was the core asset that drove the subsequent $10 billion acquisition of Onyx Pharmaceuticals. • Immune Design provided valuable, next-generation platform technology to Merck, a leader in immunotherapy, to advance their cancer and vaccine pipelines. His current position at Tempest Therapeutics—where the company is now officially "exploring strategic alternatives" (i.e., a sale or major partnership) after generating promising clinical data—fits perfectly with this successful playbook of advancing assets to a high-value inflection point for a strategic exit.
0 · Reply
Ueberschlaefer
Ueberschlaefer Oct. 24 at 8:07 PM
$TPST peeps on here are the best. the other boards suck, but you guys and gals are switched on. ty! https://youtu.be/-aMCzRj3Syg?si=IBwzUZu8s9P7K9fD
1 · Reply
Xamayca
Xamayca Oct. 24 at 7:59 PM
$TPST Intuition is goi g nuts right now hmm!
0 · Reply
fiddledjinn
fiddledjinn Oct. 24 at 7:43 PM
$TPST gotta be next week, right??
1 · Reply
Xamayca
Xamayca Oct. 24 at 6:54 PM
$TPST Shaking the tree going into power hour buy more!
1 · Reply
jonnyTH
jonnyTH Oct. 24 at 6:53 PM
$TPST December options and management bonuses timeline are getting closer and something needs to happen soon for Executives to get it as it takes 30-60 of change of control and all to vest.
0 · Reply
Latest News on TPST
Tempest Therapeutics shares end wild week with 8% drop

Oct 13, 2023, 4:13 PM EDT - 2 years ago

Tempest Therapeutics shares end wild week with 8% drop


Tempest Therapeutics shares head back to earth after 4,000% gain

Oct 12, 2023, 12:49 PM EDT - 2 years ago

Tempest Therapeutics shares head back to earth after 4,000% gain


Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

Oct 12, 2023, 11:26 AM EDT - 2 years ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS AVTX MTNB


Tempest Adopts Limited Duration Stockholder Rights Plan

Oct 11, 2023, 8:01 AM EDT - 2 years ago

Tempest Adopts Limited Duration Stockholder Rights Plan


HoodyHaz
HoodyHaz Oct. 25 at 4:17 AM
$TPST $TPST Is First out of the gate then to $SLS $ALT 3 best buyout candidates!!
1 · Reply
HoodyHaz
HoodyHaz Oct. 25 at 4:05 AM
$SLS 3 most exciting buyout candidates… $SLS $ALT $TPST TPST 10x ALT 30x SLS 30x Great assets… Best Speculation Plays !! ALL VERY VERY SOON…One goes into the other 2…. Then your liftoff…
0 · Reply
Letsinvest2024
Letsinvest2024 Oct. 24 at 11:42 PM
$TPST can’t wait for my 50k reward here🥳
1 · Reply
lousjamsession
lousjamsession Oct. 24 at 9:08 PM
1 · Reply
Dannyb313
Dannyb313 Oct. 24 at 8:32 PM
$TPST The track record of the companies Stephen Brady was instrumental in selling is indeed exceptional: • Proteolix's drug, Kyprolis (carfilzomib), became a game-changing, standard-of-care drug for Multiple Myeloma and was the core asset that drove the subsequent $10 billion acquisition of Onyx Pharmaceuticals. • Immune Design provided valuable, next-generation platform technology to Merck, a leader in immunotherapy, to advance their cancer and vaccine pipelines. His current position at Tempest Therapeutics—where the company is now officially "exploring strategic alternatives" (i.e., a sale or major partnership) after generating promising clinical data—fits perfectly with this successful playbook of advancing assets to a high-value inflection point for a strategic exit.
0 · Reply
Ueberschlaefer
Ueberschlaefer Oct. 24 at 8:07 PM
$TPST peeps on here are the best. the other boards suck, but you guys and gals are switched on. ty! https://youtu.be/-aMCzRj3Syg?si=IBwzUZu8s9P7K9fD
1 · Reply
Xamayca
Xamayca Oct. 24 at 7:59 PM
$TPST Intuition is goi g nuts right now hmm!
0 · Reply
fiddledjinn
fiddledjinn Oct. 24 at 7:43 PM
$TPST gotta be next week, right??
1 · Reply
Xamayca
Xamayca Oct. 24 at 6:54 PM
$TPST Shaking the tree going into power hour buy more!
1 · Reply
jonnyTH
jonnyTH Oct. 24 at 6:53 PM
$TPST December options and management bonuses timeline are getting closer and something needs to happen soon for Executives to get it as it takes 30-60 of change of control and all to vest.
0 · Reply
Meteormook
Meteormook Oct. 24 at 6:27 PM
$TPST I can’t recall seeing the volume this low. Spread between bid and ask also has stayed fairly significant. No liquidity. The float (what little there was) seems pretty locked up and waiting for an announcement.
4 · Reply
ezimon
ezimon Oct. 24 at 6:15 PM
$TPST come on saddy12345, 15 minutes and you still have not justified your "game over" and advise that followed what kind of a fool are you?
0 · Reply
saddy12345
saddy12345 Oct. 24 at 5:57 PM
$TPST It's game over!!!! Sell while you still can!!
1 · Reply
samson12
samson12 Oct. 24 at 5:52 PM
$TPST Alright, I'll give one of you impatient crybabies a chance to sell. My offer, buying 100 shares for $10.66/share, so I can get to 4,000 (Magical Even).
3 · Reply
Xamayca
Xamayca Oct. 24 at 5:45 PM
$TPST Maybe trial update AH followed by buyout announcement Monday
0 · Reply
brotherearl
brotherearl Oct. 24 at 5:35 PM
$TPST rocket Monday...hold on..
1 · Reply
sstock22
sstock22 Oct. 24 at 5:03 PM
$TPST you all ready for a real power-hour this afternoon? It looks like it's on the edge of breakout, just do it already! 😂 so many are waiting! Drop news, anything!
1 · Reply
simplehumble
simplehumble Oct. 24 at 4:53 PM
$TPST - This pattern is clear as daylight. Next ER (Nov 10-11): Big news -> Blue line , Positive news -> Red Line
2 · Reply
beacher
beacher Oct. 24 at 4:24 PM
$TPST Regarding Roche: It seems there are problems with the pricing within the US. I was in the Call and Roche couldn't/ didn't want to answer questions regarding this topic..
7 · Reply
samson12
samson12 Oct. 24 at 3:15 PM
$TPST Bought another 100 shares @ $10.63 Now 100 shares away from 4,000 shares.
0 · Reply
GreylockSec
GreylockSec Oct. 24 at 1:34 PM
$TPST ..Roche: WE'RE NOT DONE YET! dated 10/23/25 ...."...Roche still has some deals to do after two high profile agreements in recent weeks: “We’re not done with BD,” CEO Thomas Schinecker said during a third quarter earnings call on Thursday. Schinecker did not specify which potential partners Roche has its eye on or what particular spaces it wants to deal in. “We can continue to invest in [business development] ..."
7 · Reply
Craynos
Craynos Oct. 24 at 9:50 AM
$TPST I dont know why everyone is suggesting that TPST is running out of cash in Dezember. They reported 14.3 Mil end of Q2 2025 with a cash burn rate of 16.5 Mil for the first half of 2025. But that was with 25 full time employees and R&D for TPST 1120/1495. As of April they reduced employees to just 5 and furthermore these or at least CEO/CFO) stepped back from operating to consulting roles. One chief researcher also went to Bayer recently, so thats only 4 left. As you can already enroll to the TPST 1120 programm for p3 in collaboration with Roche, someone is already funding this clinical trial and it is not TPST itself as they obviously dont have 100-150 Mil to do that alone. They have paid all debt and cleaned the house for a new owner. The only cash they need is to pay MTS to get the deal done and did a direct offering of additional 4.6 Mil in June. I find nothing related in the last earnings release from 11th August that points to a cash runway this Dezember.
3 · Reply